about
Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance MeasuresBarriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities.Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetesObesity, bariatric surgery and type 2 diabetes--a systematic review.Practical guidance to insulin management.Practical aspects and considerations when switching between continuous subcutaneous insulin infusion and multiple daily injections.Screening, evaluation and management of depression in people with diabetes in primary care.Intensifying insulin therapy: what options are available to patients with type 2 diabetes?Insulin stacking versus therapeutic accumulation: understanding the differences.Clinical use of insulin degludec.Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.How good is your glucose control?Stepwise addition of prandial insulin.The association of hypoglycaemia severity and clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin.Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiated on basal insulin.Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study.Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA.Role of Devices in Insulin Delivery.Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-AnalysisMore patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-LRates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING StudyContinued use of an integrated meter with electronic logbook maintains improvements in glycemic control beyond a randomized, controlled trialClarification of the similarities and differences among insulin analog preparations: response to Becker"Will I have to be on insulin for the rest of my life?": IntroductionBariatric intervention effective at reversing Type 2 diabetesInsulin therapy for type 2 diabetesMultilevel Variation in Diabetes Screening Within an Integrated Health SystemCommencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulinTowards a better understanding of postprandial hyperglycemic episodes in people with diabetes: impact on daily functioningThe Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world settingHypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world settingA randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE studyInsulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomised, pragmatic real-life clinical trial
P50
Q33727441-77ED02FF-C1E9-4A6F-A044-8E014ADC60FCQ34558840-210A3EB1-D5F5-4E96-8AC8-6BE584266BB0Q34987849-E2BB3726-66A9-4FE8-AA17-96A35CFA9775Q35896348-8EF7E6AB-35C6-46FD-813C-1F1BBADCBF22Q37731636-379565C4-2387-4992-BA9F-6CE97D143A89Q37761915-3D86AF8B-D761-44FF-841B-9D346234CB6DQ38070967-092A0E06-C3D8-4D5A-8FFE-AE6B8FB0C55DQ38129490-C3BB977D-0D7D-4FDA-8474-80ED5CF9D153Q38135295-64B22ED8-5F72-4119-B81A-723DEE6EEF78Q38473629-A43FE26D-BD61-4843-A0B0-9021571E8A3FQ43115605-09CC417D-EC9A-478D-AD60-E7D3065EBE86Q43594566-FFC7D6AB-F45F-4271-9740-E8E9AF176343Q45814394-C37037E8-2A0E-4493-82B5-4BAF1FAF627EQ47188930-57ECDBAA-D1E2-4A64-AECD-07232D3CF81CQ47248324-886A6D40-2999-40A8-AB8D-001F03FAE441Q51373587-5BD29A50-7E9B-4DF5-9AEE-9AADC6C034F8Q53726559-1ED4FD8C-83B0-4DF9-A520-E2D31C8701DDQ54629685-61DFBEE8-B305-4A31-A3E8-FA495BD7DE99Q58753011-79FD4E3B-AAB8-469A-8B86-58FDD0492216Q60707174-D4D769CF-C564-4B4A-8B40-6E14ED1169A4Q64282776-F6BC1381-88BF-45A6-8988-379F8D0DB573Q80463357-0C5883F8-A3E8-4D8C-99B8-2A6A18D12940Q80702597-8A146401-81E5-404A-BB32-0D72F12F7A3BQ84068341-809C6412-0824-4E5B-9B26-D2665948BDEEQ84873515-EB94BCF5-193B-4648-A86A-B527C65160EDQ85298842-7D936F48-9DD6-47B7-B638-11911282960FQ90088989-FE38A985-2AAB-428E-9375-2BF622E8A077Q90297958-8B0927F9-98F7-4EF2-94A3-25FE034D56F8Q91202577-78E59312-D751-4611-901A-70A54B8F203DQ91476807-C9247059-4A71-4F71-9B81-66950F600B14Q91622025-FA282CBF-E416-477D-A78A-CE272E13D989Q91787174-8B2FA177-EF67-4A4A-A290-56014FCBC405Q92391763-E7EB68E7-DF0F-43C3-84D6-AD7DD19DA549Q96350337-CBEA894A-B058-4A01-960D-17C74C4AB3A0
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Luigi F Meneghini
@ast
Luigi F Meneghini
@en
Luigi F Meneghini
@es
Luigi F Meneghini
@nl
type
label
Luigi F Meneghini
@ast
Luigi F Meneghini
@en
Luigi F Meneghini
@es
Luigi F Meneghini
@nl
prefLabel
Luigi F Meneghini
@ast
Luigi F Meneghini
@en
Luigi F Meneghini
@es
Luigi F Meneghini
@nl
P106
P21
P31
P496
0000-0003-4539-2725